The newly launched Bespoke Gene Therapy Consortium (BGTC), part of the NIH Accelerating Medicines Partnership (AMP) program, aims to optimize and streamline the gene therapy development process to help fill the unmet medical needs of people with rare diseases.
Source: NIH
NIH, FDA and 15 Private Organizations Join Forces to Increase Effective Gene Therapies for Rare Diseases
Published in Psychiatric
More from PsychiatricMore posts in Psychiatric »
- Extramural Research Community Listening Session: Town Hall
- Understanding Psychology's Integrative Themes: Introduction
- The NIMH Director’s Innovation Speaker Series: Addressing Social Determinants to Optimize Infant Brain Development
- Director’s Innovation Speaker Series: Addressing Social Determinants to Optimize Infant Brain Development
- Is it time to rename schizophrenia?